Rifonat®

Intravenous rifamycin.

First-line antituberculosis drug.

Efficient presentation of an effective antituberculosis drug.

Drug administration by intravenous infusion provides 100 % bioavailability and maximum concentrations in blood and tissues.

This ensures the highest effectiveness of treatment and minimizes the risk of pathogen resistance.

The drug can be inhaled.

How supplied:

  • Concentrate for infusion solution 30 mg/ml.
  • 5 ml, 15 ml and 20 ml vials (150 mg, 450 mg and 600 mg of rifamycin).
  • 15 ml and 20 ml vials (450 mg and 600 mg of rifamycin), solvent included.
Sales markets

Azerbaijan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, Ukraine.